NEW YORK (GenomeWeb News) - Myriad Genetics said today that it plans to spin off its drug development businesses from its molecular diagnostics business, creating two separate publicly traded firms.
The company’s core molecular diagnostics business will operate under the name Myriad Genetics, will employ around 800 staffers, and will focus on the company’s stable of molecular diagnostic tests, which include BRACAnalysis, COLARIS, COLARIS AP, MELARIS, and TheraGuide 5-FU.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.